Supplemental Tables 1 and 2, Supplemental Figures 1-11 from Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2

Authors:

Abstract
Supplemental Table 1. Antibodies used for immunofluorescence Supplemental Table 2. Antibodies used for western blotting Supplemental Figure 1: EO-MCF7 sEVs decrease MCF7 proliferation. Supplemental Figure 2: Primary EO sEVs regulate MDA-MB-231 S-phase entry. Supplemental Figure 3: EO sEVs suppress breast cancer cell proliferation more than other EO-derived soluble factors. Supplemental Figure 4: Paclitaxel does not induce pronounced DNA damage in MDA-MB-231 cells. Supplemental Figure 5: Primary EO sEVs protect MDA-MB-231 cells from doxorubicin-induced DNA damage. Supplemental Figure 6: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 breast cancer cells. Supplemental Figure 7: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and MC3T3-E1 cells. Supplemental Figure 8: Non-specific binding did not occur with antibodies in-vivo in bones injected with MDA-MB-231GFP/Luc2 and EO-231 cells. Supplemental Figure 9: ERK2 is a key regulator of proliferation in MDA-MB-231 cells. Supplemental Figure 10: ERK2 regulates cellular sensitivity to chemotherapy-induced cell death. Supplemental Figure 11: miR-148a-3p regulates levels of p27 but not p21.